PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24552773-7	2014	Furthermore, ponatinib abrogated the phosphorylation of beta-catenin at the site Y654, suppressed the translocation of beta-catenin, and inhibited the transcription and DNA binding of TCF and the expression of its targets (e.g., AXIN2, c-MYC, and CCND1).	ponatinib	13-22	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	236-241	
29899872-9	2018	Phospho-FGFR and MYC, major targets of ponatinib and BET inhibitors, were downregulated after treatment with single drugs.	ponatinib	39-48	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	17-20	
29899872-10	2018	Remarkably, ponatinib was found to sensitize cells to BET antagonists by enhancing apoptotic cell death, and this effect was associated with downregulation of MYC.	ponatinib	12-21	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	159-162	
32184020-0	2020	Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.	ponatinib	65-74	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	21-26	
32184020-4	2020	PNT induced apoptosis (increased sub G1 cells, and cleaved caspase3 and PARP), and suppressed protein expression of MCL1, cyclin D2 and c-myc, which were reversed by a proteasome inhibitor, MG132, suggesting enhanced proteasomal degradation by PNT.	ponatinib	0-3	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	136-141